← All trials
NCT05825924
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2024
- Primary completion
- Mar 31, 2025
- Completion date
- Mar 31, 2025
- First posted
- Apr 24, 2023
- Last posted
- Nov 21, 2023
- Enrollment
- 258
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Foundation for a Smoke-Free WorldLead sponsor
- Foundation for a Smoke-Free WorldReponsible party - principal investigator
- Foundation for a Smoke-Free WorldSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.